Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Meiragtx Ocular UK Limited has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are distributed across 2 distinct examiners and 2 distinct art units. This indicates that each pending application is being reviewed by a different examiner in a different specialized group. The involvement of 2 distinct art units suggests that the company's biotechnology filings cover multiple specialized technical niches.
RIGA, MICHAEL ANGELO is the busiest examiner for the company, with 1 pending office action. This means the 2 pending office actions are split evenly between the 2 distinct examiners. Practitioners should prepare for different examination styles, as no single examiner or art unit controls more than one of the 2 pending office actions. The presence of 2 distinct examiners for 2 pending actions indicates that the company is receiving feedback from multiple officials across its current pending workload.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RIGA, MICHAEL ANGELO | 1 | 56.2% | +63.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18578626 | RETGC Gene Therapy | RIGA, MICHAEL ANGELO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18578626 | RETGC Gene Therapy | RIGA, MICHAEL ANGELO | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18578626 | RETGC Gene Therapy | RIGA, MICHAEL ANGELO | 1634 | §102§103 | Non-Final OA | — | Pending | Jan 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMeiragtx Ocular UK Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael Angelo Riga has the most, with 1 of Meiragtx Ocular UK Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
